VIENNA—Robot-assisted radical prostatectomy (RARP) for localized prostate cancer (PCa) offers “highly satisfactory” five-year oncologic outcomes, according to investigators.
A research team led by Nazareno Suardi, MD, of the University Vita-Salute San Raffaele in Milan, Italy, studied 184 patients with organ-confined PCa who underwent RARP. All patients had at least five years of follow-up. The mean follow-up was 69.3 months.
Five years post-operatively, one patient died from their cancer and 10 died from other causes. The mean time to biochemical recurrence (BCR) was 83.8 months. The five- and seven-year BCR-free survival rates were 84% and 81%, respectively.
The five-year BCR-free survival rate was 87% and 68% for patients with negative and positive surgical margins, respectively, and 90%, 84%, and 43% for those with organ-confined disease, extracapsular extension (ECE), and seminal vesicle invasion (SVI), and 88%, 82%, and 65% for men with pathologic Gleason scores of 2-6, 7, and 8-10, Dr. Suardi reported at the 26th Annual Congress of the European Association of Urology. These results are comparable to those reported in the literature for conventional laparoscopic surgery, Dr. Suardi said.
Subjects had a mean age of 61.9 years. At final pathology, 117 (62.5%), 56 (30%), and 14 (7.5%) had organ-confined tumors, ECE, and SVI, respectively.
The researchers identified positive surgical margins in three patients (2.5%) with organ-confined tumors and 26 (37%) with non-organ-confined tumors.